Program
Memantine
Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.
Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.
Drug pageMemantine: every studyMany companies study it; this page follows only the 27 they lead. All 198 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 130 open or running | phase 4since Jun 6, 2006 | Dec 1, 2004 | none ahead |
| H. Lundbeck | 60 open or running | phase 4since Mar 3, 2009 | Mar 3, 2009 | none ahead |
| Merz Pharmaits history only | 40 open or running | phase 4since Mar 27, 2008 | Feb 14, 2008 | none ahead |
| Carnot Laboratoriesits history only | 10 open or running | phase 4since Feb 11, 2026 | Feb 11, 2026 | none ahead |
| Gedeon Richter Plc.its history only | 10 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Geropharmits history only | 10 open or running | phase 1since Apr 18, 2017 | Apr 18, 2017 | none ahead |
| Mendel AIits history only | 10 open or running | phase 3since Jan 30, 2021 | Jan 30, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of H. Lundbeck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 3, 2009First studies: 2 phase 4 studiesFirst studyNCT00855686, NCT00862940
- Mar 5, 20092 phase 3 studies in Alzheimer DiseaseNCT00857649, NCT00857233
- Sep 16, 2015Phase 4 study in Alzheimer DiseaseNCT02553928 · 62 enrolled · China
- Sep 12, 2018Phase 1 study in HealthyNCT03670095 · 64 enrolled · China
TargetBeta
“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule
Other programs on the same 7 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esketaminerule | Johnson & Johnson | phase 4 | 51 |
Studies
All 6 H. Lundbeck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03670095Healthy · China | 1 | Completed | Dec 24, 2018 | 64 |
| NCT02553928Alzheimer Disease · China | 4 | Completed | Jul 2016 | 62 |
| NCT00862940Alzheimer Disease | 4 | Completed | Feb 2009 | 277 |
| NCT00857649Alzheimer Disease · Canada | 3 | Terminated | Apr 2010 | 369 |
| NCT00857233Alzheimer Disease · Canada | 3 | Terminated | Jul 2010 | 297 |
| NCT00855686Lewy Body Disease · Germany | 4 | Completed | Dec 2008 | 199 |
How it is read
Names in the registry
- “Memantine”, 11 entries
- “Memantine Hydrochloride (HCl)”, 4 entries
- “memantine”, 3 entries
- “memantine HCl”, 3 entries
- “Memantine HCl”, 2 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 14 studies
- Autistic Disorder, 3 studies
- Autism Spectrum Disorder, 2 studies
- Glaucoma, Open-Angle, 2 studies
- Cancer Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.